The Excel Stent: A Good DES, But Can We Really Stop Clopidogrel After 6 Months?⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.  by Margolis, James R.
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he Excel Stent: A Good DES,
ut Can We Really Stop
lopidogrel After 6 Months?*
ames R. Margolis, MD
iami, Florida
n their report of the CREATE (Multi-Center Registry of
xcel Biodegradeable Polymer Drug-Eluting Stents) study
n this issue of JACC: Cardiovascular Interventions, Han et
l. (1) suggest that the Excel stent (JW Medical System,
eihai, China)—a sirolimus-eluting stent with biodegrad-
ble polymer—has equal or superior major adverse cardiac
vent (MACE) rates to presently available drug-eluting
tents (DES). Because the biodegradable polymer precludes
ate stent thrombosis (LST), only 6 months of clopidogrel
re required. This is a well-designed study performed in a
cientific manner. The data are reported objectively, and the
uthors recognize the deficiencies of a registry. Upon first
eading, the results are impressive. On closer inspection, it is
ecessary to ask what the study actually showed, and is there
ny solid evidence that Excel is superior to presently
vailable DES?
See page 303
The authors conclude that the outcomes of the present
tudy demonstrate:
Satisfactory efficacy and safety profiles for the Excel
biodegradable polymer-based sirolimus-eluting stent in
treating patients in “real-world” settings, with low rates
of MACE and stent thrombosis up to 18 months.
The outcomes also suggest that 6 months of dual
antiplatelet therapy with clopidogrel and aspirin after
Excel stent implantation is safe and feasible.
Although I agree with the first conclusion, I do not
elieve that the data support the conclusion that it is safe to
top clopidogrel and aspirin 6 months after Excel stent
mplantation.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-S
ions or the American College of Cardiology.
From Miami International Cardiology Consultants, Miami, Florida.he Excel Stent
he Excel stent has a sirolimus coating bound to an S-Stent
Biosensors International, Singapore). The S-Stent is a stain-
ess steel stent that is said to provide superior deliverability in
mall and tortuous vessels. The unusually low early MACE
ate in this study suggests that this claim may be true. The
iodegradable polymer is polylactic acid. The coating can be
xpected to degrade fully in 6 to 9 months. The authors
ypothesize that degradation of the polymer coating will
ecrease inflammation around the stent, thereby reducing late
ypersensitivity and decreasing the risk of in-stent thrombosis.
here are limited clinical or even animal data to support this
ypothesis. These include 1 well-documented case report of
eath due to LST with a prolific eosinophilic reaction (2), and
recent report of 4 possible cases derived from reports of
dverse events in Food and Drug Administration databases (3).
ST in DES
he problem of LST with DES is a real one, and its
mportance cannot be overemphasized. The occurrence is well
ocumented (4–6). The causes are generally understood (7).
lthough the incidence is low, and possibly no different than
ith bare-metal stents (6), LST with DES frequently results in
ajor myocardial infarction or death (4).
LST with DES has been correlated with incomplete stent
ndothelialization, and stent underexpansion (7). Long-term
lopidogrel appears to reduce the problem, but this has not
een demonstrated in prospective studies. Because LST in
ES can occur even several years after stent implantation,
here is no universal agreement as to how long clopidogrel
dministration is necessary.
The idea that LST is related to the polymer coating used to
ind drug in DES is attractive but entirely unproven. The
nderlying problem seems to be incomplete healing with
ontinuing exposure of metallic stent surfaces (7). Incomplete
ealing may persist for years, especially if small amounts of
esidual drug remain. Biodegradable polymer coating might
itigate this problem by assuring the disappearance of residual
rug, but this is also unproven.
esults of the CREATE Study
nd Comparison With Other Studies
umulative MACE rates in the CREATE study were 0.9% at 30
ays, 2.7% at 1 year, and 3.7% at 18 months. MACE beyond 30
ays was 1.8% at 1 year and 2.8% at 18 months. These data
ompare favorably with those from comparable studies: the SIR-
US (Sirolimus-Eluting Stent in Coronary Lesions) study
-month MACE 7.3% (8); the TAXUS IV study 12-month
ACE 10.8% (9); the SYNTAX (The Synergy Between Per-
utaneous Coronary Intervention With TAXUS and Cardiac
urgery) study 12-month MACE 17.8% (10).
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Margolis
Editorial Comment
311Much of the advantage in the CREATE registry is ac-
ounted for by the very low initial MACE rates: 0.9% 30 days
ersus 2.4% in the SIRIUS study (8), 2.5% in the TAXUS IV
tudy (9), and 4% in the SYNTAX study (10). Even taking the
bove into account, there still appears to be an advantage for
xcel in comparison with Cypher and Taxus: Excel 30 days to
year MACE 1.8%; Cypher 30 days to 9 months 5.1% (8);
axus 30 days to 12 months 8.3% (9).
The low early MACE rates in the CREATE study may
e explained by a number of factors:
. Lesion and clinical characteristics
. Skill of the investigators
. Under-reporting of events
. Differences between registries and randomized studies
. Favorable characteristics of the S-Stent and its delivery
system
With the available data there is no way to judge the role
f #1, #2, and #3. Data from previous Cypher registries
peak to #4. The 30-day MACE rate for Cypher was 2.4%
n the U.S. SIRIUS trial (8), but only 1.0% in a post-market
urveillance study (11).
The favorable deliverability of the S-Stent is the most
ikely explanation for low MACE rates in the CREATE
egistry. Similarly low MACE rates were seen in studies of
ience V (30-day MACE 1.5% in the Spirit III [Clinical
valuation of the Xience V Everolimus Eluting Coronary
tent System in the Treatment of Patients With de novo
ative Coronary Artery Lesions] study [12]) (Abbott Vas-
ular, Abbot Park, Illinois) and Endeavor (30-day MACE
.2% in the Endeavor IV [Randomized Comparison of
otarolimus-Eluting and Paclitaxel-Eluting Stents in Pa-
ients With Coronary Artery Disease] study [13])
Medtronic, Inc., Minneapolis, Minnesota)—2 DES whose
eliverability are superior to that of Cypher and TAXUS.
Although it is difficult to compare registry studies to
andomized studies, the CREATE data suggest an advan-
age for the Excel stent. In the population studied, and in
he hands of the CREATE study investigators, the initial
ACE rates are incredibly low—not only in comparison
ith other DES studies, but also compared with studies
omparing stenting to medical or surgical management
e.g., 30-day MACE for the COURAGE [Clinical Out-
omes Utilizing Revascularization and Aggressive Drug
valuation] study 2.5% [14], the SYNTAX study 4% [10]).
With the effectiveness of most DES in reducing target
esion revascularization to extremely low levels, initial
ACE rates are increasingly relevant. This is especially true
n multivessel stenting, where MACE rates are directly
roportional to the number of vessels stented (10). The
bility of second generation DES to reduce early MACE
hrough improved deliverability may be more important
han any subtle differences in drug effect. that Can We Say About the Excel Stent?
f the CREATE data are reproducible, the Excel stent has a
ery low initial MACE rate, presumably due to its excellent
eliverability, and it has a target lesion revascularization rate
omparable to or better than other DES. The study is too small
nd the follow-up too short to make a meaningful comment in
egard to LST after only 6 months of clopidogrel—especially
n light of the fact that 1 LST occurred only 4 days after
lopidogrel discontinuation.
Whether or not the biodegradable polymer coating is effective
n promoting late healing is not addressed in this study, since there
as no evaluation of these patients with either intravascular
ltrasound or optical coherence tomography.
eprint requests and correspondence: Dr. James R. Margolis,
iami International Cardiology Consultants, 3801 Biscayne Bou-
evard, Miami, Florida 33137. E-mail: jmargolis@jrmpa.com.
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